Melanoma is a severe form of skin cancer arising from melanocytes. In recent years, immunotherapy in particular, immune checkpoint inhibitor (ICI), has revolutionized the treatment of metastatic melanoma. Recent studies have explored the potential of treatment of metastatic melanoma using the combination of ICI with radiotherapy (RT). In present study, we systematically review available clinical studies involving the combination of RT with pembrolizumab. A systematic search using the electronic databases including PubMed, Scopus, and Embase was conducted to retrieve relevant clinical studies investigating the use of RT+ pembrolizumab on metastatic melanoma patients. Results showed that a total of 16 studies involving 612 metastatic melanoma patients were included. Furthermore, the treatment combination was generally safe with grade 3 or higher toxicities ranging from 1 to 11%. In conclusion, this therapeutic modality is promising. However, gray areas such as limited prospective studies and optimal timing will need to be addressed in future studies.

中文翻译：

---

放射疗法与派姆单抗联合治疗转移性黑色素瘤患者的系统评价

黑色素瘤是由黑色素细胞引起的皮肤癌的一种严重形式。近年来，免疫疗法特别是免疫检查点抑制剂（ICI）彻底改变了转移性黑色素瘤的治疗方法。最近的研究探索了使用ICI与放疗（RT）结合治疗转移性黑色素瘤的潜力。在本研究中，我们系统地回顾了涉及RT与pembrolizumab组合的可用临床研究。使用包括PubMed，Scopus和Embase在内的电子数据库进行系统搜索，以检索相关的临床研究，以研究RT + pembrolizumab在转移性黑色素瘤患者中的使用。结果显示，总共纳入了612例转移性黑色素瘤患者的16项研究。此外，该治疗组合通常是安全的，3级或更高的毒性范围为1至11％。总之，这种治疗方式是有希望的。但是，在未来的研究中将需要处理诸如前瞻性研究有限和最佳时机这样的灰色领域。